A phase II trial of interleukin-12 in patients with advanced cervical cancer: Clinical and immunologic correlates: Eastern Cooperative Oncology Group study E1E96

Gynecologic Oncology

Volumn 92, Issue 3, 2004, Pages 957-964

  Wadler, Scott ^a   Levy, Donna ^b   Frederickson, Helen L ^c   Falkson, Carla I ^d   Wang, Yuexian ^e   Weller, Edie ^b   Burk, Robert ^e   Ho, Gloria ^e   Kadish, Anna S ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CCOP Colorado Cancer Research Program   (United States)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cell mediated immunity; Cytokine; Human papillomavirus

Indexed keywords

CISPLATIN; PEPTIDE DERIVATIVE; RECOMBINANT INTERLEUKIN 12; VIRUS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEHYDRATION; DIARRHEA; DOSE RESPONSE; EDEMA; EFFUSION; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; IMMUNOLOGY; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG EDEMA; LUNG TOXICITY; MENTAL DISEASE; METASTASIS; MOTOR DYSFUNCTION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; ONCOLOGY; OUTPATIENT; PAIN; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; STROKE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA; VOMITING; WEIGHT GAIN;

EID: 1342343087     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.12.022     Document Type: Article

References (41)

1. Cannistra S.A., Niloff J.M. Cancer of the uterine cervix. N. Engl. J. Med. 334:1996;1030-1038.
2. Greenlee R., Hill-Harmon M., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 51:2001;15-37.
3. Omura G.A. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. J. Natl. Cancer Inst. Monogr. 1996;123-126.
4. Moore D., McQuellon R., Blessing J., Thaler H., Benda J., Miller D.et al. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Proc. Am. Soc. Clin. Oncol. 20:2001;201a.
5. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M.et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327:1992;1272-1278.
6. Schiffman M.H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 84:1992;394-398.
7. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J.et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87:1995;796-802.
8. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V.et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19.
9. Liaw K.L., Glass A.G., Manos M.M., Greer C.E., Scott D.R., Sherman M.et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J. Natl. Cancer Inst. 91:1999;954-960.
10. Morrison E.A., Ho G.Y., Vermund S.H., Goldberg G.L., Kadish A.S., Kelley K.F.et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int. J. Cancer. 49:1991;6-13.
11. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnurch H.G., zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. U. S. A. 80:1983;560-563.
12. Durst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. U. S. A. 80:1983;3812-3815.
13. Crook T., Morgenstern J.P., Crawford L., Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 8:1989;513-519.
14. Pecoraro G., Morgan D., Defendi V. Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 86:1989;563-567.
15. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:1989;934-937.
16. Howley P.M., Munger K., Werness B.A., Phelps W.C., Schlegel R. Molecular mechanisms of transformation by the human papillomaviruses. Princess Takamatsu Symp. 20:1989;199-206.
17. Scheffner M., Munger K., Byrne J.C., Howley P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5523-5527.
18. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
19. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P.et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1995;1365-1371.
20. Chen Y., Sidney J., Southwood S., Cox A.L., Sakaguchi K., Henderson R.A.et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol. 152:1994;2874-2881.
21. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W.et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
22. Kadish A.S., Ho G.Y., Burk R.D., Wang Y., Romney S.L., Ledwidge R.et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89:1997;1285-1293.
23. Kadish A.S., Romney S.L., Ledwidge R., Tindle R., Fernando G.J., Zee S.Y.et al. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. J. Gen. Virol. 75(Pt. 9):1994;2277-2284.
24. Kadish A.S., Timmins P., Wang Y., Ho G.Y., Burk R.D., Ketz J.et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol. Biomarkers Prev. 11:2002;483-488.
25. Evans E.M., Man S., Evans A.S., Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:1997;2943-2950.
26. Wadler S., Burk R.D., Neuberg D., Rameau R., Runowicz C.D., Goldberg G. et al. Lack of efficacy of interferon-alpha therapy in recurrent, advanced cervical cancer. J. Interferon Cytokine Res. 15:1995;1011-1016.
27. Robertson M.J., Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist. 1:1996;88-97.
28. Trinchieri G., Wysocka M., D'Andrea A., Rengaraju M., Aste-Amezaga M., Kubin M.et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog. Growth Factor Res. 4:1992;355-368.
29. Soiffer R.J., Robertson M.J., Murray C., Cochran K., Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 82:1993;2790-2796.
30. Zeh H.J. III, Hurd S., Storkus W.J., Lotze M.T. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunother. 14:1993;155-161.
31. Manetti R., Gerosa F., Giudizi M.G., Biagiotti R., Parronchi P., Piccinni M.P.et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J. Exp. Med. 179:1994;1273-1283.
32. Ozmen L., Aguet M., Trinchieri G., Garotta G. The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon. J. Virol. 69:1995;8147-8150.
33. Gerosa F., Paganin C., Peritt D., Paiola F., Scupoli M.T., Aste-Amezaga M.et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J. Exp. Med. 183:1996;2559-2569.
34. Coughlin C.M., Wysocka M., Kurzawa H.L., Lee W.M., Trinchieri G., Eck S.L. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55:1995;4980-4987.
35. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M.et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1993;1223-1230.
36. Brunda M.J., Luistro L., Rumennik L., Wright R.B., Dvorozniak M., Aglione A.et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol. 38:1996;S16-S21. [Supplement].
37. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S.et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3:1997;409-417.
38. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B.et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548.
39. Institute N.C. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, NCI, NIH; 1988.
40. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T.et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
41. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.